Tagbo RN, Verma H, Mahmud ZM, et al. - Via performing an open-label, two-arm, non-inferiority, multi-center, randomized controlled trial in Nigeria, researchers here investigated the immunogenicity of the new bOPV + IPV immunization schedule and gains in type 2 immunity with addition of a second dose of IPV. The trial was performed in August 2016-March 2017 period, well past the tOPV-bOPV switch in April 2016. They enrolled and randomized 572 infants (aged ≤ 14 days) into two arms: infants in Arm A were administered bOPV at birth, 6 and 10 weeks, bOPV+IPV at week 14 and IPV at week 18 and in Arm B were administered IPV each at 6, 10, 14 weeks and bOPV at 18 weeks of age. Findings from this first trial on the new EPI schedule in a sub-Saharan African country establish excellent immunogenicity against poliovirus types 1 and 3, and substantial/improved immunogenicity against poliovirus type 2 following 1 to 2 doses of IPV respectively.